Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

Old API Wind-down Ltd - Ordinary Shares > Earnings announcement soon...
View:
Post by kuatolives on Feb 21, 2017 6:14pm

Earnings announcement soon...

I hope?
Comment by GoldenDilemma on Feb 21, 2017 10:39pm
Mid-March likely. Horizon reports next week. This will give us some intel though Yosprala is our saviour. 
Comment by snootchybootchy on Feb 23, 2017 1:24pm
I'm thinking it will be Tuesday next week.  For Q1 through Q3, Aralez has reported earnings one day after Horizon.  Horizon is scheduled to report on the 27th of this month.
Comment by kuatolives on Feb 23, 2017 1:37pm
They also usually announce it one or two weeks in advance, which is why I was wondering.
Comment by snootchybootchy on Feb 24, 2017 2:57pm
I watched the webcast of the presentation Aralez presented at the RBC Markets Global Healthcare Conference.  Mr. Adams mentioned (a few times) that the year-end conference call will be scheduled for early March. Not sure if it was my imagination but he seemed to be playing down any potential over-exuberance regarding the uptake of Yosprala.  He mentioned several times that they're ...more  
Comment by kuatolives on Feb 24, 2017 6:09pm
I think 2017 will be the end of this ride for me if profitability isn't achieved and the needle doesn't start to move. I aint gonna live forever.
Comment by PoorOpinion on Feb 27, 2017 10:06pm
I just noticed in the new presentation that they dropped the page entitled "Early performance indicators" which had been in the two previous presentations and was showing sales of Yosprala. My guess is you pull it out if the numbers arent so hot, you leave it in and update it if things are on track. Over-exuberance may well be off the table.
Comment by GoldenDilemma on Feb 28, 2017 9:41am
Light a candle and say a prayer for good earnings. Below $2 if bad. 
Comment by kuatolives on Feb 28, 2017 9:59am
for 130M in earnings, $2 would put it at roughly 1x earnings, which I doubt for a company that claims profitability in 2017. Anyhoo, I stopped trying to read the tea leaves last year. I, for one, will be happy to see some numbers. Biotech looks to be back on the upswing again.
Comment by GoldenDilemma on Feb 28, 2017 10:12am
Traded rangebound from Oct 1st 2015 - Q4 readouts in March 2016 and then look what happened. While I do not expect there to be as significant of a loss, do not put it past shorts if Yosprala numbers and revenue growth is not delivering.  We know what the YTD bottom is.. as do shorts. Expect it to break on unfavourable earnings. 
Comment by GoldenDilemma on Feb 28, 2017 10:13am
Sorry, did not add - we are trading rangebound right now as well. 
Comment by kuatolives on Feb 28, 2017 11:43am
I don't think many will care about 2016 as much as the 2017 projection, that is, unless the actuals came in well under the estimates.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities